Moclobemide was compared with clomipramine for safety and efficacy in 2 groups of 15 patients each with endogenous depression. The drugs were given under double‐blind conditions in increasing doses; 1 patient in the moclobemide group dropped out because of lack of efficacy. Mean final improvement on the Hamilton Rating Scale for Depression was 51% in the moclobemide group and 54% in the clomipramine group. Efficacy and tolerance were rated good or very good by 47% (moclobemide) and 53%o (clomipramine) (NS). The results indicate that moclobemide is as effective as clomipramine in treating endogenous depression.
Depressed outpatients (n = 107, age 26-75 years) were treated with either a 50 mg single morning dose of diclofensine (n = 54) or 75-100 mg nomifensine given in two divided doses (n = 53) over a period of three weeks. The baseline mean values of the Depression Status Inventory (DSI index) of Zung corresponded to those of a mildly depressed population, as given by Zung. At the end of the treatment the mean DSI and Anxiety Status Inventory (ASI-index) values of both groups dropped to the levels of a normal population. The side-effect profile of the two treatments was similar. There were no side-effects indicating sedation. Adverse effects of the anticholinergic type were rare. It can be concluded that both diclofensine and nomifensine are beneficial for the treatment of depressed outpatients and that in a dose relation of 2:3 (diclofensine:nomifensine) they lead to a similar improvement in depressive outpatients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.